AURA AURA BIOSCIENCES INC

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences:

  • The Citizens Life Sciences Conference on Thursday, May 8, 2025.

    Fireside Chat at 9:30 a.m. ET.
  • H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025.

    Fireside Chat at 2:00 p.m. ET.
  • TD Cowen 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025.

    Fireside Chat at 10:00 a.m. ET.



The live webcasts of the fireside chats will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at , where a replay of each webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visit . Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Investor and Media Contact:

Alex Dasalla

Head of Investor Relations and Corporate Communications



EN
01/05/2025

Underlying

AURAAURA BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AURA BIOSCIENCES INC

 PRESS RELEASE
Free
AURA AURA BIOSCIENCE...

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference on Thursday, May 8, 2025.Fireside Chat at 9:30 a.m. ET. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025.Fireside Chat...

May 1, 2025 1 EN
 PRESS RELEASE
Free
AURA AURA BIOSCIENCE...

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of D...

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our Board of Directors,” said Elisabet de los Pinos, Chief Executive Officer of Aura Biosciences. “She...

April 2, 2025 1 EN
 PRESS RELEASE
Free
AURA AURA BIOSCIENCE...

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial R...

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress; Supports Front-Line Treatment Potential Clinical Pipeline Continues to Advance with Phase 3 CoMpass Trial Actively Enrolling Phase 2 Trial in Metastases to the Choroid Initiated Cash Position Expected to Support Operations into 2H 2026 BOSTON, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AURA), a clinical-stage biotechnology company dev...

March 24, 2025 1 EN
 PRESS RELEASE
Free
AURA AURA BIOSCIENCE...

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscl...

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC Aura Hosting with Key O...

March 24, 2025 1 EN
 PRESS RELEASE
Free
AURA AURA BIOSCIENCE...

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial ...

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precisi...

March 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch